# Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment

> **NCT06323837** · PHASE2 · RECRUITING · sponsor: **Washington State University** · enrollment: 60 (estimated)

## Conditions studied

- Stimulant Use Disorder

## Interventions

- **DRUG:** Mirtazapine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06323837
- **Lead sponsor:** Washington State University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-17
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06323837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06323837, "Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06323837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*